Literature DB >> 22369391

An overview of treatment of overactive bladder syndrome in women.

S Allahdin1, N Oo.   

Abstract

Overactive bladder syndrome (OAB) is a common, often under-reported and under-treated condition that significantly affects the quality of life (QoL) of the sufferer and is associated with enormous related costs. Treatments options for OAB include lifestyle modifications, behavioural therapy, pharmacotherapy, neuromodulation, Botulinum toxin therapy and surgical interventions. For this paper, the Embase, Cochrane and Medline databases were searched for studies relating to the treatment options for OAB with (urge urinary incontinence) UUI from 1975 to 2010. Studies were also obtained from references of published reviews. Search terms used for retrieval were: overactive bladder syndrome, urge urinary incontinence, anticholinergics, Botulinum toxin A, sacral neuromodulation and clam bladder augmentation. The aim of this paper is to provide an overview of the treatment options currently available for women with OAB.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22369391     DOI: 10.3109/01443615.2011.649317

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  6 in total

1.  Communicating under medical patriarchy: gendered doctor-patient communication between female patients with overactive bladder and male urologists in Hong Kong.

Authors:  Judy Yuen-Man Siu
Journal:  BMC Womens Health       Date:  2015-05-29       Impact factor: 2.809

2.  "Seeing a doctor is just like having a date": a qualitative study on doctor shopping among overactive bladder patients in Hong Kong.

Authors:  Judy Yuen-Man Siu
Journal:  BMC Fam Pract       Date:  2014-02-06       Impact factor: 2.497

3.  Communicating with mismatch and tension: treatment provision experiences of primary care doctors treating patients with overactive bladder in Hong Kong.

Authors:  Judy Yuen-Man Siu
Journal:  BMC Fam Pract       Date:  2015-10-30       Impact factor: 2.497

4.  Hengli® Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Limin Liao; Qinggang Liu; Huiling Cong; Zhihui Xu; Enhui Li; Zhiliang Weng; Haihong Jiang; Ben Liu; Xiao Huang; Shujie Xia; Wei Wen; Juan Wu; Guowei Shi; Yang Wang; Peijun Li; Yang Yu; Zujun Fang; Jie Zheng; Ye Tian; Donghao Shang; Hanzhong Li; Zhongming Huang; Liqun Zhou; Yunxiang Xiao; Yaoguang Zhang; Jianlong Wang; Xiaodong Zhang; Peng Zhang; Dongwen Wang; Xuhui Zhang; Keji Xie; Bin Wang; Lulin Ma; Xiaojun Tian; Lijun Chen; Jinkai Dong
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

5.  Is overactive bladder independently associated with anxiety?

Authors:  Shambe Mutungi; Jacqueline Parrish; Robert Maunder; May Alarab; Colleen D McDermott; Nucelio Lemos; Danny Lovatsis
Journal:  Int Urogynecol J       Date:  2019-07-13       Impact factor: 2.894

6.  Eight-Year Experience With Botulinum Toxin Type-A Injections for the Treatment of Nonneurogenic Overactive Bladder: Are Repeated Injections Worthwhile?

Authors:  Shannon Hk Kim; David Habashy; Sana Pathan; Vincent Tse; Ruth Collins; Lewis Chan
Journal:  Int Neurourol J       Date:  2016-03-16       Impact factor: 2.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.